Episode

392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA

Podcast
The Readout Loud
Published
Mar 12, 2026
Duration seconds
1851
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/TTSAA4013999142.mp3?updated=1773339038
Audio
https://traffic.megaphone.fm/TTSAA4013999142.mp3?updated=1773339038
JSON
/v1/public/podcasts/the-readout-loud-1134305/episodes/392-epstein-s-pal-attempts-a-biotech-comeback-and-prasad-exits-the-fda
Markdown
/podcast/the-readout-loud-1134305/392-epstein-s-pal-attempts-a-biotech-comeback-and-prasad-exits-the-fda.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/392-epstein-s-pal-attempts-a-biotech-comeback-and-prasad-exits-the-fda/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-readout-loud-1134305/392-epstein-s-pal-attempts-a-biotech-comeback-and-prasad-exits-the-fda.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

How was a known friend of Jeffrey Epstein able to raise $100 million, with the help of a prominent biotech VC? And will Vinay Prasad return to the Food and Drug Administration for a "three-peat"? Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor with deep ties to Jeffrey Epstein, who has raised a new biotech investment firm. The hosts also talk about Prasad's second exit from the FDA and a congressman's probing of the agency's rare disease drug denials. And they recap Novo Nordisk and Hims' detente and Xenon Pharmaceuticals' promising seizure data.